Abstract
Immunodeficient mice reconstituted with human CD4+ T cells, which can be achieved either by transfer of mature cells or immature progenitors, represent the only animal model to study HIV-1 infection of human lymphocytes in vivo. However, the immunocompromised status of most of these models currently rule out their use for vaccine studies. Nevertheless, the model might be ideally suited for HIV-1 gene therapy studies since eliciting an efficient anti-viral immune response is not the primary end-point. Rather, HIV-1 gene therapy should protect CD4+ T cells from HIV-1- induced deletion and/or reduced viral replication. Here, we describe recent advancements in the field of HIV-1 gene therapy, focusing on tools and targets validated in various models of humanized mice. From the analysis of this literature, it appears that strategies targeting viral entry, by means of neutralizing antibodies or fusion inhibitors, are the most promising so far. Indeed, strategies targeting viral entry have moved to the clinic with encouraging results. Thus, humanized mice should be considered as the prime model to devise the safer and most effective HIV-1 gene therapy strategy.
Keywords: HIV-1, Gene therapy, Humanized mice, CCR5, CD4+ T cells, DNA, RAG.
Current Gene Therapy
Title:Lessons From HIV-1 Gene Therapy in Humanized Mice: Is Targeting Viral Entry the Road to Success?
Volume: 16 Issue: 1
Author(s): Nicolas Petit and Gilles Marodon
Affiliation:
Keywords: HIV-1, Gene therapy, Humanized mice, CCR5, CD4+ T cells, DNA, RAG.
Abstract: Immunodeficient mice reconstituted with human CD4+ T cells, which can be achieved either by transfer of mature cells or immature progenitors, represent the only animal model to study HIV-1 infection of human lymphocytes in vivo. However, the immunocompromised status of most of these models currently rule out their use for vaccine studies. Nevertheless, the model might be ideally suited for HIV-1 gene therapy studies since eliciting an efficient anti-viral immune response is not the primary end-point. Rather, HIV-1 gene therapy should protect CD4+ T cells from HIV-1- induced deletion and/or reduced viral replication. Here, we describe recent advancements in the field of HIV-1 gene therapy, focusing on tools and targets validated in various models of humanized mice. From the analysis of this literature, it appears that strategies targeting viral entry, by means of neutralizing antibodies or fusion inhibitors, are the most promising so far. Indeed, strategies targeting viral entry have moved to the clinic with encouraging results. Thus, humanized mice should be considered as the prime model to devise the safer and most effective HIV-1 gene therapy strategy.
Export Options
About this article
Cite this article as:
Petit Nicolas and Marodon Gilles, Lessons From HIV-1 Gene Therapy in Humanized Mice: Is Targeting Viral Entry the Road to Success?, Current Gene Therapy 2016; 16 (1) . https://dx.doi.org/10.2174/1566523216666160104141644
DOI https://dx.doi.org/10.2174/1566523216666160104141644 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial (Thematic Issue: Helicobacter pylori Eradication Therapy: Advantages and Disadvantages)
Current Pharmaceutical Design Dietary Approaches and Alternative Therapies for Rheumatoid Arthritis
Current Nutrition & Food Science The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Current Topics in Medicinal Chemistry The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Anti-Cancer Agents in Medicinal Chemistry From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Voltage-Gated Sodium Channels: New Targets in Cancer Therapy?
Current Pharmaceutical Design Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Medicinal Chemistry Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Natural Products Chemistry in Marine Ascidians of the Genus Aplidium
Mini-Reviews in Organic Chemistry Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science